Evaluation of the analgesic efficacy of AZD1940, a novel cannabinoid agonist, on post-operative pain after lower third molar surgical removal

@article{Kalliomki2013EvaluationOT,
  title={Evaluation of the analgesic efficacy of AZD1940, a novel cannabinoid agonist, on post-operative pain after lower third molar surgical removal},
  author={Jarkko Kalliom{\"a}ki and M{\"a}rta Segerdahl and Lynn R. Webster and Annika Reimfelt and Karin Huizar and Peter Annas and Rolf Karlsten and Hans Quiding},
  journal={Scandinavian Journal of Pain},
  year={2013},
  volume={4},
  pages={17 - 22}
}

Figures from this paper

Evaluation of the analgesic efficacy and psychoactive effects of AZD1940, a novel peripherally acting cannabinoid agonist, in human capsaicin‐induced pain and hyperalgesia

The emergence of mild dose‐dependent CNS effects suggests that the dose range predicted from preclinical data had been attained, and no evidence of analgesic efficacy was found for a peripherally acting CB1/CB2 receptor agonist in the human capsaicin pain model.

Analgesic efficacy of cannabinoids for acute pain management after surgery: a systematic review and meta-analysis

The quantitative and qualitative review of the literature suggests that the analgesic role of perioperative cannabinoid compounds is limited, with no clinically important benefits detected when cannabinoids are added to traditional systemic analgesics compared with traditional systemic painkillers alone.

Cannabinoids in the Management of Acute Pain: A Systematic Review and Meta-analysis.

There is low-quality evidence indicating that cannabinoids may be a safe alternative for a small but significant reduction in subjective pain score when treating acute pain, with intramuscular administration resulting in a greater reduction relative to oral.

Weeding Out the Problem: The Impact of Preoperative Cannabinoid Use on Pain in the Perioperative Period.

It is shown that cannabinoid use was associated with higher pain scores and a poorer quality of sleep in the early postoperative period in patients undergoing major orthopedic surgery.

Cannabis and orofacial pain: a systematic review.

Cannabinoids in the Treatment of Back Pain.

This review will provide an overview on the pharmacology, drug delivery methods, clinical evidence, and safety considerations critical to understanding the potential role of cannabinoids in the treatment of back pain.

Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials.

The evidence neither supports nor refutes claims of efficacy and safety for cannabinoids, cannabis, or CBM in the management of pain.

Cannabis-based medicines and the perioperative physician

A summary of the pharmacology of cannabis-based medicines including anaesthetic interactions and implications is presented, to assist colleagues encountering these medicines in clinical practice.

Cannabinoids for Pain Modulation in Orthopedic Surgery.

There is limited high-quality evidence of the efficacy of cannabinoids in treating orthopedic-related pain, and as cannabis becomes more accessible, well-designed trials are needed to better understand cannabinoids and guide orthopedics practice.

Comparison of the Onset of Diclofenac Potassium Sachet(Voltfast) and EntericCoated Diclofenac Potassium(Cataflam) in Treatment of Pain Following Tooth Extraction

Oral diclofenac is an effective treatment for moderate to severe postoperative pain and significantly more participants experienced a faster onset of pain relief with voltfast than with cataflam.

References

SHOWING 1-10 OF 44 REFERENCES

Effects of nabilone, a synthetic cannabinoid, on postoperative pain

  • P. Beaulieu
  • Medicine
    Canadian journal of anaesthesia = Journal canadien d'anesthesie
  • 2006
High dose nabilone in the presence of morphine patient controlled analgesia is associated with an increase in pain scores in patients undergoing major surgery, contrary to the main hypothesis.

A Multicenter Dose-escalation Study of the Analgesic and Adverse Effects of an Oral Cannabis Extract (Cannador) for Postoperative Pain Management

These significant dose-related improvements in rescue analgesia requirements in the 10 mg and 15 mg groups provide a number needed to treat that is equivalent to many routinely used analgesics without frequent adverse effects.

Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial.

In this preliminary study, CT-3 was effective in reducing chronic neuropathic pain compared with placebo and no major adverse effects were observed.

A model to evaluate mild analgesics in oral surgery outpatients

Both aspirin 650 mg and acetaminophen 600 mg proved superior to placebo (p < 0.01) for all measures of effect with both parametric or nonparametric analyses, while codeine 30 mg was not significantly inferior to placebo in any analysis.

Lack of effect of central nervous system‐active doses of nabilone on capsaicin‐induced pain and hyperalgesia

The aim of the present study was to investigate the effects of nabilone on capsaicin‐induced pain and hyperalgesia, as well as on biomarkers of cannabinoid central nervous system (CNS) effects. A

The Efficacy of Preoperative Versus Postoperative Rofecoxib for Preventing Acute Postoperative Dental Pain: A Prospective Randomized Crossover Study Using Bilateral Symmetrical Oral Surgery

Rofecoxib is an excellent analgesic for preventing postoperative dental pain and when given 2 hours preoperatively rendered most patients relatively pain free, requiring no rescue analgesics on the first postoperative day.

Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial

Dronabinol has a modest but clinically relevantanalgesic effect on central pain in patients with multiple sclerosis and on the SF-36 quality of life scale, the two items bodily pain and mental health indicated benefits from active treatment compared with placebo.